Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 27)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
9-Feb-10 New Constructs, LLC N/A INFI: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
9-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for INFI: the economy's impact on INFI's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
9-Feb-10 ValuEngine, Inc. N/A ValuEngine Industry Report for DRUGS 18 $49 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
8-Feb-10 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for INFI 13 $25 View Abstract
8-Feb-10 Market Edge N/A Market Edge Equity Research Report 4 $10 View Abstract
8-Feb-10 PriceTarget Research, Inc. N/A INFI has a current Overall Rating of C (Neutral). 7 $25 View Abstract
7-Feb-10 Pechala's Reports Frantisek Pechala INFINITY PHARMACEUTICALS INC (INFI=US) 12-months forecast 1 $15 View Abstract
7-Feb-10 PriceTarget Research, Inc. N/A Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. 65 $20 View Abstract
Next 17

Brokerage Reports (Showing 1 to 2 of 2)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
4-Jan-10 Roth Capital Partners, Inc. Research Department Morning Call Summary 13 $50 View Abstract
4-Jan-10 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino PhD A 2010 Catalyst Calendar Of Roth Biotech Coverage 8 $25 View Abstract

Independent Reports (Showing 1 to 10 of 25)

Release
Date Contributor Author Title Pages Price More Info
9-Feb-10 New Constructs, LLC N/A INFI: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
9-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for INFI: the economy's impact on INFI's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
9-Feb-10 ValuEngine, Inc. N/A ValuEngine Industry Report for DRUGS 18 $49 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
8-Feb-10 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for INFI 13 $25 View Abstract
8-Feb-10 Market Edge N/A Market Edge Equity Research Report 4 $10 View Abstract
8-Feb-10 PriceTarget Research, Inc. N/A INFI has a current Overall Rating of C (Neutral). 7 $25 View Abstract
7-Feb-10 Pechala's Reports Frantisek Pechala INFINITY PHARMACEUTICALS INC (INFI=US) 12-months forecast 1 $15 View Abstract
7-Feb-10 PriceTarget Research, Inc. N/A Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. 65 $20 View Abstract
Next 15

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.